STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
STAT
JANUARY 31, 2024
Meanwhile, do keep us in mind if you hear anything interesting. In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S. And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started.
Let's personalize your content